Mankind Pharma Limited (NSE:MANKIND)
India flag India · Delayed Price · Currency is INR
2,472.00
-103.90 (-4.03%)
Jul 31, 2026, 3:30 PM IST

Mankind Pharma Financials Overview

Millions INR. Fiscal year is Apr - Mar.

Revenue & Profits

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
147,379142,776122,074102,60487,49477,816
Revenue Growth
14.16%16.96%18.98%17.27%12.44%25.22%
Gross Profit
104,286100,13085,39969,54957,46352,937
Operating Income
30,21528,19125,08321,50215,88318,322
Net Income
20,42719,12919,91019,12912,81914,335
Earnings Per Share
49.4246.2849.1947.6832.0035.78
EPS Growth
6.48%-5.92%3.16%49.02%-10.57%13.27%

Revenue by Geography

Fiscal YearFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '25 Mar '24 Mar '23 Mar '22
India
122,164106,75094,47084,47075,947
Outside India
20,61315,3258,1352,9581,868
Total
142,776122,074102,60487,42977,816

Cash & Debt

Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
22,07722,07724,96233,86515,21612,793
Total Debt
63,11563,11585,1152,0721,7048,836
Net Cash (Debt)
-41,039-41,039-60,15331,79313,5123,957
Net Cash Growth
---135.29%241.51%-77.06%
Net Cash Per Share
-99.29-99.29-148.6379.2533.739.88

Cash Flow & CapEx

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
-31,21324,13421,52418,1339,198
Capital Expenditures
--6,260-4,608-3,153-7,890-4,649
Free Cash Flow
-24,95319,52618,37110,2434,549
Free Cash Flow Growth
-27.80%6.29%79.36%125.16%-45.31%

Margins

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
70.76%70.13%69.96%67.78%65.68%68.03%
Operating Margin
20.50%19.74%20.55%20.96%18.15%23.55%
Pretax Margin
17.38%16.34%20.61%23.37%19.10%25.38%
Profit Margin
13.86%13.40%16.31%18.64%14.65%18.42%
FCF Margin
-17.48%16.00%17.90%11.71%5.85%

Dividends

Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingAug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Dividend Per Share
2.000-----
Dividend Per Share Growth
0%-----

Valuation

Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingAug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PE Ratio
49.9743.2950.2548.18--
Forward PE
41.1035.5345.1343.88--
P/FCF Ratio
40.8733.1851.2450.17--
PS Ratio
6.925.808.208.98--